Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02425826 · ClinicalTrials.gov registry record · Phase 4
A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.
A Phase 4 study of Parapsoriasis, sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 221
- Enrollment target
- 20
- Study locations
NCT02425826 is a Phase 4 study of Parapsoriasis that has completed, run by Amgen. The registered enrollment target is 221 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT02425826, a Phase 4 study of Parapsoriasis, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 221 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the clinical efficacy, the patients quality of life, and safety of oral apremilast 30 mg twice daily (BID) compared to placebo, in adult patients with moderate plaque psoriasis during the 16 week Placebo controlled Phase and then upto 1 year in the Extension Phase of the trial.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Apremilast
- DRUG Placebo-Apremilast
Study Locations (20)
California
- Center For Dermatology - Fremont
- Dermatology Research Associates - Los Angeles
- Blue Harbor Dermatology - Newport Beach
- Center for Dermatology and Laser Surgery - Sacramento
- East Bay Rheumatology Medical - San Leandro
- Tien Q. Nguyen MD Inc - Tustin
Florida
- Dermatology Associates - Panama City
- USF Health Faculty Office Building-FOB - Tampa
- Forward Clinical Trials Inc - Tampa
Kentucky
- Dermatology Specialists, PSC - Louisville
- DermResearch, PLLC - Louisville
Alabama
- UAB at Birmingham - The Kirklin Clinic - Birmingham
Connecticut
- UConn Health Center - Farmington
Georgia
- Dermatologic Surgery Specialists, P.C. - Macon
Indiana
- Shideler Clinical Research Center - Carmel
Maryland
- Lawrence Green, MD, LLC - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2015-04-20 |
| Est. Completion | 2016-11-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02425826
The ClinicalTrials.gov registry entry for NCT02425826 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parapsoriasis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02425826 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT02425826 about?
NCT02425826 is a clinical study titled "A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.". This study will evaluate the clinical efficacy, the patients quality of life, and safety of oral apremilast 30 mg twice daily (BID) compared to placebo, in adult patients with moderate plaque psoriasis during the 16 week Placebo controlled Phase and then upto 1 year in the Extension Phase of the tri...
What is the current status of trial NCT02425826?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 221 participants. The study started on 2015-04-20. Estimated completion is 2016-11-22.
What conditions does trial NCT02425826 study?
This clinical trial studies the following conditions: Parapsoriasis.
What interventions are being tested in trial NCT02425826?
The interventions under investigation include: Placebo (DRUG), Apremilast (DRUG), Placebo-Apremilast (DRUG).
Who is sponsoring clinical trial NCT02425826?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02425826 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.